Serum lncRNA (Malat-1) discriminates active from remission Crohn’s disease with sensitivity of 76.47% and specificity of 70.59% at a cutoff value of > 47.92.
Can serum lncRNA (malat1) serve as a biomarker for disease activity in patients with Crohn's disease?
Serum lncRNA (Malat-1) is a potential biomarker for assessing disease activity in patients with Crohn's disease.
Absolute Event Rate: 0% vs 0%
Abstract Background Long non-coding RNA (lncRNA) has a role in epigenetic, transcriptional, post-transcriptional, and translational control, as well as post-translational modification Therefore, this study aimed to investigate the role of serum lncRNA (malat1) as a marker of disease activity in patients with Crohn’s disease. Methods This case-control prospective study was performed on 49 individuals categorized in Group I: which included thirty-four patients with Crohn’s disease who were subdivided into 2 subgroups: (Group Ia includes 17 patients with active Crohn’s disease, and Group Ib includes 17 patients with Crohn’s disease in remission). Group II: included 15 healthy individuals as controls. Results In group I, there was a statistically significant lower Hb level, greater PLT and WBC count, ESR, and CRP than in group II. The mean FC level was normal in the control group, high in group I, and shooting in active patients, and these variations were statistically significant. There was a strong positive correlation between serum lncRNA and calprotectin in all studied groups. The total group showed a significant correlation between Malat-1 and both CDAI and SES-CD, with no significant correlations between CRP and serum lncRNA. Serum lncRNA can discriminate Patients with active Crohn’s disease from Patients with Crohn’s disease in remission at the cut-off value at a cutoff value of 47.92. The sensitivity, specificity, PPV, and NPV were 76.47%, 70.59%, 72.2%, and 75%, respectively (p 0.001). Conclusion Serum lncRNA (Malat-1) correlates well with disease activity indicators and can be used to measure disease activity in CD patients. References: 1. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s gastrointestinal and liver disease—2 volume set: pathophysiology, diagnosis, management. Philadelphia: Saunders; 2015. 2. Leong RWL. The significance of granulomas in Crohn’s disease and inflammatory bowel disease epidemiology in Asia. J Gastroenterol Hepatol. 2020;35(4):523-4. https://doi.org/10.1111/jgh.15018. 3. Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct. 2020;15(1):23. https://doi.org/10.1186/s13062-020-00280-5. 4. Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology. 2022;162(3):715-30.e3 https://doi.org/10.1053/j.gastro.2021.10.035. Conflict of interest: Dr. Abdelaziz, Mohamed Ahmed: No conflict of interest saeed, Ahmed: No conflict of interest elkaany, Ahmed Ismaael: No conflict of interest Dewidar, Fatima: No conflict of interest Ibrahim, Abeer: No conflict of interest
Abdelaziz et al. (Thu,) reported a other. Serum lncRNA (Malat-1) discriminates active from remission Crohn’s disease with sensitivity of 76.47% and specificity of 70.59% at a cutoff value of > 47.92.